| __timestamp | AstraZeneca PLC | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 11606000000 |
| Thursday, January 1, 2015 | 11451000000 | 10313000000 |
| Friday, January 1, 2016 | 9739000000 | 9762000000 |
| Sunday, January 1, 2017 | 10543000000 | 9830000000 |
| Monday, January 1, 2018 | 10362000000 | 10102000000 |
| Tuesday, January 1, 2019 | 11848000000 | 10615000000 |
| Wednesday, January 1, 2020 | 11693000000 | 8955000000 |
| Friday, January 1, 2021 | 15680000000 | 9634000000 |
| Saturday, January 1, 2022 | 18955000000 | 10042000000 |
| Sunday, January 1, 2023 | 18025000000 | 10504000000 |
| Monday, January 1, 2024 | 20532000000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AstraZeneca PLC and Merck & Co., Inc. have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses surged by approximately 35%, peaking in 2022. This reflects their aggressive market expansion and strategic investments. In contrast, Merck's expenses remained relatively stable, with a slight decline of about 10% over the same period, indicating a more conservative approach. Notably, AstraZeneca's expenses consistently surpassed Merck's, highlighting their differing operational strategies. These insights provide a window into how these pharmaceutical giants allocate resources to maintain their market positions and drive growth.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited